warfarin and Tricuspid-Valve-Stenosis

warfarin has been researched along with Tricuspid-Valve-Stenosis* in 3 studies

Other Studies

3 other study(ies) available for warfarin and Tricuspid-Valve-Stenosis

ArticleYear
Valvular heart disease in Antiphospholipid antibody syndrome: Isolated Tricuspid stenosis.
    Echocardiography (Mount Kisco, N.Y.), 2019, Volume: 36, Issue:3

    Antiphospholipid antibody syndrome (APLS) is a rare disorder characterized by a hypercoagulable state. Manifestations include arterial or venous thrombosis, recurrent fetal wastage, coronary artery disease, valvular heart disease, dilated cardiomyopathy, pulmonary artery hypertension, and intracardiac thrombus. Most commonly mitral valve is affected followed by aortic and then tricuspid valve. In this report, a rare case of spontaneous aortic thrombosis with tricuspid stenosis uncomplicated by other valve lesions is presented with clinical and echocardiographic studies and computed tomographic images.

    Topics: Adult; Antiphospholipid Syndrome; Echocardiography, Doppler; Echocardiography, Transesophageal; Female; Heart Valve Diseases; Humans; Tricuspid Valve; Tricuspid Valve Stenosis; Warfarin

2019
Thrombosis of a mechanical tricuspid valve prosthesis resolved with fibrinolysis.
    Revista espanola de cardiologia (English ed.), 2014, Volume: 67, Issue:12

    Topics: Drug Therapy, Combination; Echocardiography, Three-Dimensional; Enoxaparin; Female; Fibrinolytic Agents; Heart Valve Prosthesis; Humans; Middle Aged; Thrombolytic Therapy; Thrombosis; Tricuspid Valve; Tricuspid Valve Stenosis; Warfarin

2014
Tricuspid valve replacement. Fifteen years of experience with mechanical prostheses and bioprostheses.
    The Journal of thoracic and cardiovascular surgery, 1995, Volume: 109, Issue:6

    Tricuspid valve replacement is not a common operation. The purpose of this study was to examine the early and late results in 60 patients who underwent 28 (47%) bioprosthetic and 32 (53%) mechanical tricuspid valve replacements. All operations took place between January 1978 and June 1993 during which period a total of 4741 patients underwent valve replacement operation. Mean patient age was 50 +/- 15 (18 to 75) years. Forty-one patients (68%) were female and 19 patients (32%) were male. Forty-nine patients (82%) were in New York Heart Association class III or IV before operation. Forty-five patients (75%) were undergoing repeat cardiac valve operation. Seventeen patients (28%) had complex congenital cardiac problems. Operation was urgent in 15 patients (25%). The hospital mortality rate was 27% (16 patients). All patients with hospital death were in New York Heart Association class III or IV, were having repeat operations, or had complex congenital disease. Low output syndrome was observed in 21 patients (35%). Reoperation because of bleeding was required in seven patients (12%). Thirteen patients (22%) required permanent (epicardial lead) pacemaker implantation. Mean follow-up is 75 +/- 45 months (maximum 173 months) and 100% complete for the 44 patients who left the hospital. There have been 14 deaths (32%). Nine of these patients (64%) had mechanical valves and five (36%) had bioprostheses. Of the 11 cardiac deaths, three were valve related (bioprostheses). Three patients (10%) required reoperation because of tricuspid valve prosthetic failure (1 thrombosed mechanical valve, 2 failed porcine valves). Of the remaining 30 patients, 20 (67%) are in New York Heart Association class I or II. Seventeen patients have mechanical valves and 13 have bioprostheses. Twenty-six patients (90%) are receiving warfarin. Thromboembolism (transient ischemic attack) has occurred in one patient with a mechanical valve who also had a previous cerebrovascular accident. In this group there has been no hemorrhage, endocarditis, or new pacemaker requirement. Actuarial survival for the whole series is 37% +/- 9% and for the hospital survivors is 50% +/- 12% at 15 years. Linearized rates of valve-related complications are not different between groups. Tricuspid valve replacement is a beneficial procedure for patients with structural tricuspid valve disease, many of whom have other valvular or congenital disease. Contemporary mechanical prostheses and bioprostheses are equally ef

    Topics: Bioprosthesis; Female; Follow-Up Studies; Heart Valve Prosthesis; Hospital Mortality; Humans; Life Tables; Male; Middle Aged; Postoperative Complications; Prosthesis Design; Registries; Reoperation; Time Factors; Tricuspid Valve; Tricuspid Valve Insufficiency; Tricuspid Valve Stenosis; Warfarin

1995